MedinCell Valuation Multiples

MedinCell Overview

About MedinCell

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Founded

2003

HQ

Employees

143

Website

medincell.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $38M

EBITDA: ($3M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

MedinCell Financials

MedinCell reported last 12-month revenue of $38M and negative EBITDA of ($3M).

In the same LTM period, MedinCell generated ($3M) in EBITDA losses and had net loss of ($14M).

MedinCell P&L

In the most recent fiscal year, MedinCell reported revenue of $30M and EBITDA of ($13M).

MedinCell expects next 12-month revenue of XXX and NTM EBITDA of XXX

MedinCell Stock Performance

MedinCell has current market cap of $1B, and enterprise value of $1B.

MedinCell's stock price is $28.40.

MedinCell Valuation Multiples

MedinCell trades at 26.6x EV/Revenue multiple, and (293.5x) EV/EBITDA.

MedinCell Financial Valuation Multiples

As of April 18, 2026, MedinCell has market cap of $1B and EV of $1B.

Equity research analysts estimate MedinCell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

MedinCell has a P/E ratio of (71.3x).

MedinCell Margins & Growth Rates

MedinCell's revenue in the last 12 month grew by 61%.

MedinCell's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

MedinCell's rule of 40 is 81% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

MedinCell's rule of X is 158% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

MedinCell Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

MedinCell M&A Activity

MedinCell acquired XXX companies to date.

Last acquisition by MedinCell was on XXXXXXXX, XXXXX. MedinCell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

MedinCell Investment Activity

MedinCell invested in XXX companies to date.

MedinCell made its latest investment on XXXXXXXX, XXXXX. MedinCell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).